| Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by anti-histo-blood group antibodies P Guillon, M Clément, V Sébille, JG Rivain, CF Chou, N Ruvoën-Clouet, ... Glycobiology 18 (12), 1085-1093, 2008 | 497 | 2008 |
| Real-time RT-PCR for norovirus screening in shellfish F Loisy, RL Atmar, P Guillon, P Le Cann, M Pommepuy, FS Le Guyader Journal of virological methods 123 (1), 1-7, 2005 | 467 | 2005 |
| Bile-salt-stimulated lipase and mucins from milk of ‘secretor’mothers inhibit the binding of Norwalk virus capsids to their carbohydrate ligands N Ruvoën-Clouet, E Mas, S Marionneau, P Guillon, D Lombardo, ... Biochemical Journal 393 (3), 627-634, 2006 | 100 | 2006 |
| Intrarectal immunization with rotavirus 2/6 virus-like particles induces an antirotavirus immune response localized in the intestinal mucosa and protects against rotavirus … D Agnello, CA Hervé, A Lavaux, M Darniot, P Guillon, A Charpilienne, ... Journal of virology 80 (8), 3823-3832, 2006 | 65 | 2006 |
| Association between expression of the H histo-blood group antigen, α1, 2fucosyltransferases polymorphism of wild rabbits, and sensitivity to rabbit hemorrhagic disease virus P Guillon, N Ruvoën-Clouet, B Le Moullac-Vaidye, S Marchandeau, ... Glycobiology 19 (1), 21-28, 2009 | 58 | 2009 |
| The approved pediatric drug suramin identified as a clinical candidate for the treatment of EV71 infection—suramin inhibits EV71 infection in vitro and in vivo P Ren, G Zou, B Bailly, S Xu, M Zeng, X Chen, L Shen, Y Zhang, P Guillon, ... Emerging microbes & infections 3 (1), 1-9, 2014 | 57 | 2014 |
| Targeting human respiratory syncytial virus transcription anti-termination factor M2-1 to inhibit in vivo viral replication B Bailly, CA Richard, G Sharma, L Wang, L Johansen, J Cao, ... Scientific reports 6 (1), 25806, 2016 | 55 | 2016 |
| Multidisciplinary approaches identify compounds that bind to human ACE2 or SARS-CoV-2 spike protein as candidates to block SARS-CoV-2–ACE2 receptor interactions CJ Day, B Bailly, P Guillon, L Dirr, FEC Jen, BL Spillings, J Mak, ... MBio 12 (2), 10.1128/mbio. 03681-20, 2021 | 52 | 2021 |
| Structure-guided discovery of potent and dual-acting human parainfluenza virus haemagglutinin–neuraminidase inhibitors P Guillon, L Dirr, IM El-Deeb, M Winger, B Bailly, T Haselhorst, JC Dyason, ... Nature communications 5 (1), 5268, 2014 | 41 | 2014 |
| The Catalytic Mechanism of Human Parainfluenza Virus Type 3 Haemagglutinin‐Neuraminidase Revealed L Dirr, IM El‐Deeb, P Guillon, CJ Carroux, LMG Chavas, M von Itzstein Angewandte Chemie 127 (10), 2979-2983, 2015 | 40 | 2015 |
| Infection-associated FUT2 (Fucosyltransferase 2) genetic variation and impact on functionality assessed by in vivo studies LM Silva, AS Carvalho, P Guillon, S Seixas, M Azevedo, R Almeida, ... Glycoconjugate journal 27, 61-68, 2010 | 36 | 2010 |
| Widespread gene conversion of alpha-2-fucosyltransferase genes in mammals J Abrantes, D Posada, P Guillon, PJ Esteves, J Le Pendu Journal of molecular evolution 69, 22-31, 2009 | 29 | 2009 |
| New antiviral approaches for human parainfluenza: Inhibiting the haemagglutinin-neuraminidase VP Chibanga, L Dirr, P Guillon, IM El-Deeb, B Bailly, RJ Thomson, ... Antiviral Research 167, 89-97, 2019 | 28 | 2019 |
| In-vitro antiviral activity of a novel phthalic acid ester derivative isolated from the Bangladeshi mangrove fern Acrostichum aureum SJ Uddin, J Bettadapura, P Guillon, I Darren Grice, S Mahalingam, ... J Antivir Antiretrovir 5 (6), 139-144, 2013 | 25 | 2013 |
| Exploring human parainfluenza virus type-1 hemagglutinin–neuraminidase as a target for inhibitor discovery IM El-Deeb, P Guillon, M Winger, T Eveno, T Haselhorst, JC Dyason, ... Journal of medicinal chemistry 57 (18), 7613-7623, 2014 | 23 | 2014 |
| A dual drug regimen synergistically blocks human parainfluenza virus infection B Bailly, L Dirr, IM El-Deeb, R Altmeyer, P Guillon, M von Itzstein Scientific reports 6 (1), 24138, 2016 | 19 | 2016 |
| The impact of the butterfly effect on human parainfluenza virus haemagglutinin-neuraminidase inhibitor design L Dirr, IM El-Deeb, LMG Chavas, P Guillon, M Itzstein Scientific reports 7 (1), 4507, 2017 | 15 | 2017 |
| A portable device for LAMP based detection of SARS-CoV-2 KR Sreejith, M Umer, L Dirr, B Bailly, P Guillon, M von Itzstein, N Soda, ... Micromachines 12 (10), 1151, 2021 | 14 | 2021 |
| Structural Insights into Human Parainfluenza Virus 3 Hemagglutinin–Neuraminidase Using Unsaturated 3-N-Substituted Sialic Acids as Probes M Pascolutti, L Dirr, P Guillon, A Van Den Bergh, T Ve, RJ Thomson, ... ACS chemical biology 13 (6), 1544-1550, 2018 | 11 | 2018 |
| Exploring inhibitor structural features required to engage the 216-loop of human parainfluenza virus type-3 hemagglutinin-neuraminidase IM El-Deeb, P Guillon, L Dirr, M von Itzstein MedChemComm 8 (1), 130-134, 2017 | 11 | 2017 |
Benjamin BaillyInstitute for Glycomics - Griffith UniversityVerified email at griffith.edu.au
